Cash, cash equivalents and investment securities were $229.2 million as of September 30, 2023. We anticipate that our cash, cash equivalents and investment securities as of September 30, 2023, combined with the projected revenues from BRIUMVI, will be sufficient to fund our planned operations into cash flow positivity based on the current operating plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TGTX:
- Unusually active option classes on open November 1st
- TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
- TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update
- Biotech Alert: Searches spiking for these stocks today
- TG Therapeutics call volume above normal and directionally bullish
